Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:AXLA NASDAQ:FENC NASDAQ:INMB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.19-3.4%$9.21$7.21▼$22.20$1.90B0.725.14 million shs960,135 shsAXLAAxcella Health$0.40$0.84$0.34▼$41.25$1.18M0.46267,009 shsN/AFENCAdherex Technologies$8.70$7.76$5.65▼$10.45$303.52M1.08199,301 shs23,735 shsINMBINmune Bio$1.23+1.2%$1.37$1.09▼$11.64$32.57M1.03405,812 shs35,327 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+4.43%+9.28%+7.61%-43.43%-59.35%AXLAAxcella Health0.00%0.00%0.00%0.00%0.00%FENCAdherex Technologies-0.80%-4.81%+22.54%+14.02%+4.69%INMBINmune Bio-0.82%-8.33%-10.37%-9.02%-84.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.19-3.4%$9.21$7.21▼$22.20$1.90B0.725.14 million shs960,135 shsAXLAAxcella Health$0.40$0.84$0.34▼$41.25$1.18M0.46267,009 shsN/AFENCAdherex Technologies$8.70$7.76$5.65▼$10.45$303.52M1.08199,301 shs23,735 shsINMBINmune Bio$1.23+1.2%$1.37$1.09▼$11.64$32.57M1.03405,812 shs35,327 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+4.43%+9.28%+7.61%-43.43%-59.35%AXLAAxcella Health0.00%0.00%0.00%0.00%0.00%FENCAdherex Technologies-0.80%-4.81%+22.54%+14.02%+4.69%INMBINmune Bio-0.82%-8.33%-10.37%-9.02%-84.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.33Hold$19.67140.19% UpsideAXLAAxcella Health 0.00N/AN/AN/AFENCAdherex Technologies 2.71Moderate Buy$15.4077.01% UpsideINMBINmune Bio 2.17Hold$8.00553.06% UpsideCurrent Analyst Ratings BreakdownLatest ADMA, AXLA, INMB, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Outperform$21.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$21.005/26/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/25/2026FENCAdherex Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/22/2026FENCAdherex Technologies HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $16.005/7/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.005/7/2026ADMAADMA Biologics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$24.00 ➝ $20.004/27/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/21/2026FENCAdherex Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.004/20/2026ADMAADMA Biologics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$509.86M3.72$0.66 per share12.41$2.01 per share4.07AXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AFENCAdherex Technologies$51.00M5.95N/AN/A$1.04 per share8.37INMBINmune BioN/AN/AN/AN/A$0.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6812.047.80N/A32.43%39.98%28.08%8/5/2026 (Estimated)AXLAAxcella Health-$81.19M-$19.25N/AN/AN/AN/AN/A-259.91%N/AFENCAdherex Technologies-$9.74M-$0.29N/A9.46N/A-17.12%-43.87%-11.35%8/13/2026 (Estimated)INMBINmune Bio-$45.93M-$1.67N/AN/AN/AN/A-103.03%-77.66%8/6/2026 (Estimated)Latest ADMA, AXLA, INMB, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026FENCAdherex Technologies-$0.02$0.01+$0.03$0.01$13.90 million$15.11 million5/7/2026Q1 2026INMBINmune Bio-$0.2450-$0.20+$0.0450-$0.20$1.11 millionN/A5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million3/30/2026Q4 2025INMBINmune Bio-$0.27-$0.18+$0.09-$0.18($0.01) millionN/A3/24/2026Q4 2025FENCAdherex Technologies$0.0423-$0.17-$0.2123-$0.17$14.75 million$13.78 million3/24/2026Q4 2025FENCAdherex Technologies$0.03-$0.17-$0.20-$0.17$14.73 million$13.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93AXLAAxcella HealthN/A0.800.80FENCAdherex TechnologiesN/A6.986.78INMBINmune BioN/A4.244.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AXLAAxcella Health65.07%FENCAdherex Technologies55.51%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%AXLAAxcella Health2.20%FENCAdherex Technologies10.73%INMBINmune Bio21.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableAXLAAxcella Health112.95 million2.88 millionNo DataFENCAdherex Technologies1034.89 million31.14 millionOptionableINMBINmune Bio1026.59 million20.90 millionOptionableADMA, AXLA, INMB, and FENC HeadlinesRecent News About These CompaniesINmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's TrialJune 2, 2026 | globenewswire.comINMB Share News TodayMay 19, 2026 | uk.investing.comINmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ PlatformMay 15, 2026 | globenewswire.comINmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseMay 14, 2026 | globenewswire.comINmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection PointMay 13, 2026 | globenewswire.comINmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call TranscriptMay 10, 2026 | insidermonkey.comINmune Bio (INMB) Q1 2026 Earnings TranscriptMay 8, 2026 | finance.yahoo.comINmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks TranscriptMay 8, 2026 | seekingalpha.comINmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform ...May 7, 2026 | caledonianrecord.comCINmune Bio Inc. Announces First Quarter 2026 Results and Provides Business UpdateMay 7, 2026 | globenewswire.comINmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory DiseasesMay 5, 2026 | globenewswire.comINmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7thApril 30, 2026 | globenewswire.comINmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer ModelsApril 16, 2026 | markets.businessinsider.comINMune Bio, Inc. (NASDAQ:INMB) Q4 2025 earnings call transcriptApril 1, 2026 | msn.comINmune Bio (NASDAQ:INMB) Will Have To Spend Its Cash WiselyApril 1, 2026 | finance.yahoo.comINmune Bio, Inc.: INmune Bio Inc. Announces 2025 Results and Provides Business UpdateMarch 31, 2026 | finanznachrichten.deINmune Bio Inc (INMB) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesMarch 31, 2026 | finance.yahoo.comINmune Bio Inc. (INMB) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comINmune Bio Inc. Announces 2025 Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comQuant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lagMarch 29, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADMA, AXLA, INMB, and FENC Company DescriptionsADMA Biologics NASDAQ:ADMA$8.19 -0.29 (-3.44%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Axcella Health NASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Adherex Technologies NASDAQ:FENC$8.70 0.00 (0.00%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.INmune Bio NASDAQ:INMB$1.23 +0.02 (+1.24%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Biggest Opportunity From SpaceX’s IPO May Surprise You Chewy’s Growth Engine Is Stronger Than the Market Thinks Casey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance Align 2 Ways to Play the QXO/TopBuild Deal The “Duck Stock” Keeps Quietly Making Money for Shareholders Everpure: AI Storage Uncertainty Overshadows Breakneck Growth As Shares Fall, Analyst Are Boosting their Broadcom Price Targets This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
